

Amphastar Pharmaceuticals, Inc.  
Form 3  
June 24, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â ZASLOFF MICHAEL A  
(Last) (First) (Middle)

C/O AMPHASTAR  
PHARMACEUTICALS,  
INC.,Â 11570 6TH STREET  
(Street)

RANCHO  
CUCAMONGA,Â CAÂ 91730  
(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)  
06/24/2014

3. Issuer Name and Ticker or Trading Symbol

Amphastar Pharmaceuticals, Inc. [AMPH]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer  Other  
(give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8,682	D	Â
Common Stock	5,457 <sup>(1)</sup>	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
-----------------------------------------------	-------------------------------------------------------------	------------------------------------------------------------------	---------------------------	----------------------	----------------------------------------------------------

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (2)	12/18/2015	Common Stock	38,462	\$ 11.68	D	Â
Stock Option (Right to Buy)	Â (2)	10/03/2016	Common Stock	10,381	\$ 15.23	D	Â
Stock Option (Right to Buy)	Â (2)	12/10/2016	Common Stock	37,994	\$ 14.23	D	Â
Stock Option (Right to Buy)	Â (2)	12/15/2017	Common Stock	78,624	\$ 10.77	D	Â
Stock Option (Right to Buy)	Â (3)	12/20/2018	Common Stock	29,278	\$ 14.66	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ZASLOFF MICHAEL A C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	Â X	Â	Â	Â

## Signatures

/s/Michael A. Zasloff, by Power of Attorney 06/24/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This represents deferred stock units that were granted on 12/20/2013 and fully vest on the first anniversary of the grant date.
- (2) This option is fully vested and exercisable.
- (3) This option was granted on 12/20/2013 and fully vests on the first anniversary of the grant date, subject to the reporting person's continued service on the Board of Directors of the Issuer through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.